search button
Open Access

Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection

  • Authors:
    • Pei-Yi Shen
    • Cheng-Yen Chuang
    • Chih-Hung Lin
    • Yu-Wei Hsu
    • Yen-Hsiang Huang
    • Kuo-Hsuan Hsu
    • Jeng-Sen Tseng
    • Gee-Chen Chang
    • Tsung-Ying Yang

  • View Affiliations

  • Published online on: October 29, 2024     https://doi.org/10.3892/ol.2024.14780
  • Article Number: 35

  • Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with non‑small cell lung cancer (NSCLC) and incomplete resection have poor clinical outcomes. The present study aimed to identify risk factors for disease progression and mortality. A total of 65 patients with early‑stage NSCLC that underwent operation but had a non‑R0 resection between August 2011 and December 2020 were included in the present study, and the clinicopathological features and driver gene mutation status were analyzed. The median follow‑up time was 36.2 months; 39 patients (60.0%) experienced disease progression and 3 patients (4.6%) died. In total, 22 patients (33.8%) harbored mutations in driver genes. Multivariate analysis demonstrated that the presence of driver gene mutations was associated with an increased risk of disease progression [adjusted odds ratio, 24.08; 95% confidence interval (CI), 2.77‑209.01; P=0.004]. Tumors classed as Eastern Cooperative Oncology Group performance status 2 [adjusted hazard ratio (HR), 3.49; 95% CI, 1.10‑11.03; P=0.033], stage II‑IIIB tumors (adjusted HR, 2.55; 95% CI, 1.06‑6.17; P=0.037) and the presence of a driver gene mutation (adjusted HR, 3.28; 95% CI, 1.55‑6.94; P=0.002) were associated with a significantly reduced progression‑free survival (PFS). Driver gene‑targeted therapy was associated with an increased post‑progression survival for patients that were reported to have disease progression (adjusted HR, 0.38; 95% CI, 0.16‑0.91; P=0.030). There was no significant impact of driver gene mutation status on the overall survival (OS) of patients. Although the presence of a driver gene mutation was associated with an increased risk of disease progression and a reduced PFS, it was demonstrated that patients with disease progression may benefit from driver gene‑targeted therapy, as patients with driver gene‑targeted therapy had a similar OS compared with that of patients with a driver gene‑negative or unknown status. Therefore, early comprehensive analysis of driver gene mutation status may be recommended for early‑stage NSCLC cancer patients experiencing non‑R0 resection.
View Figures
View References

Related Articles

Journal Cover

January-2025
Volume 29 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Shen P, Chuang C, Lin C, Hsu Y, Huang Y, Hsu K, Tseng J, Chang G and Yang T: Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection. Oncol Lett 29: 35, 2025.
APA
Shen, P., Chuang, C., Lin, C., Hsu, Y., Huang, Y., Hsu, K. ... Yang, T. (2025). Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection. Oncology Letters, 29, 35. https://doi.org/10.3892/ol.2024.14780
MLA
Shen, P., Chuang, C., Lin, C., Hsu, Y., Huang, Y., Hsu, K., Tseng, J., Chang, G., Yang, T."Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection". Oncology Letters 29.1 (2025): 35.
Chicago
Shen, P., Chuang, C., Lin, C., Hsu, Y., Huang, Y., Hsu, K., Tseng, J., Chang, G., Yang, T."Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection". Oncology Letters 29, no. 1 (2025): 35. https://doi.org/10.3892/ol.2024.14780